High cumulative doxorubicin dose for advanced soft tissue sarcoma

BACKGROUND: The recommended cumulative doxorubicin dose in soft tissue sarcoma (STS) treatment was based on cardiotoxicity data from retrospective studies of breast cancer patients. However, the treatment and prognosis of STS and breast cancer are quite different, and reference to breast cancer data...

Descripción completa

Detalles Bibliográficos
Autores principales: Tian, Zhichao, Yang, Yang, Yang, Yonghao, Zhang, Fan, Li, Po, Wang, Jiaqiang, Yang, Jinpo, Zhang, Peng, Yao, Weitao, Wang, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7684756/
https://www.ncbi.nlm.nih.gov/pubmed/33228579
http://dx.doi.org/10.1186/s12885-020-07663-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7684756/
https://www.ncbi.nlm.nih.gov/pubmed/33228579
http://dx.doi.org/10.1186/s12885-020-07663-x

Ejemplares similares